1. Component Analysis
This protocol mirrors the male stack but targets Hypoactive Sexual Desire Disorder (HSDD) and the body composition shifts associated with menopause/perimenopause.
- Kisspeptin-10:
- Role: Hormonal Signaling.
- Mechanism: In women, Kisspeptin regulates the release of GnRH, which triggers LH/FSH. This can stimulate the ovaries to optimize estrogen and progesterone production (and small amounts of testosterone). It is also being studied for its direct role in “limbic brain” arousal—emotional bonding and sexual receptivity.
- PT-141 (Bremelanotide):
- Role: The FDA-Approved Solution.
- Mechanism: Sold under the brand name Vyleesi, this is one of the few drugs FDA-approved specifically for HSDD in pre-menopausal women. It bypasses the vascular system and works directly on the brain to “switch on” desire.
- Melanotan-II:
- Role: Background Libido support.
- Mechanism: Similar to the male stack, it provides a background hum of dopaminergic arousal, though it is often used for its cosmetic tanning effects.
- CJC-1295 + Ipamorelin + Tesamorelin:
- Role: Body Confidence & Energy.
- Mechanism: These are all Growth Hormone secretagogues. In this context, they are used to combat the “menopausal middle” (abdominal fat gain) and improve sleep/energy, which are major factors in low libido.
2. Protocol Breakdown
Core Bundle
- Target: Women feeling “flat,” disconnected, or struggling with the physical changes of aging that impact sexual confidence.
- The Logic: This is a “Brain and Body” stack.
- PT-141/Kisspeptin target the neurological “brakes” on sex drive.
- GH Peptides (CJC, Ipa, Tesamorelin) target the physical energy and aesthetics.
